Precise identification of Tregs will allow a better comparison of their levels to potentially beneficial subsets (for tumour elimination) such as CD4 effector (CD25int) or CD8 central and effector memory T cells, particularly for those that have been activated in the patients (CD38+) [30]. The gene discussed is CD38; the disease is neoplasm.